CIK 0001870404 · <br>Emerging growth company
CERO THERAPEUTICS HOLDINGS, INC.
Sign in to watch- Tickers
- CERO CEROW
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 871088814
- Phone
- 650-407-2376
- Business address
- 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- CERO THERAPEUTICS HOLDINGS, INC., PHOENIX BIOTECH ACQUISITION CORP.
Securities
- CERO Common stock OTC
- CEROW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-04 | Francois Eric Director | Grant or award · Stock Option (Right to Buy) | +1,823,278 | 1,823,278 | ||
| 2026-01-07 | Ehrlich Christopher B Chairman and CEO | Grant or award · Stock Option (Right to Buy) | +4,530,997 | 4,530,997 | ||
| 2026-01-07 | ATWOOD BRIAN G Director | Grant or award · Stock Option (Right to Buy) | +1,612,099 | 1,612,099 | ||
| 2026-01-07 | Byrnes Michael Director | Grant or award · Stock Option (Right to Buy) | +690,900 | 690,900 | ||
| 2026-01-07 | Rolfe Lindsey Director | Grant or award · Stock Option (Right to Buy) | +690,900 | 690,900 | ||
| 2026-01-07 | KUCHARCHUK ANDREW ALBERT Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +1,162,099 | 1,162,099 | ||
| 2026-01-07 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +690,900 | 690,900 | ||
| 2026-01-07 | Patel Shami Director | Grant or award · Stock Option (Right to Buy) | +690,900 | 690,900 | ||
| 2026-01-07 | Pierce Kristen Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +1,612,099 | 1,612,099 | ||
| 2025-05-30 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +9,326 | 9,326 | ||
| 2025-05-30 | Byrnes Michael Director | Grant or award · Stock Option (Right to Buy) | +9,326 | 9,326 | ||
| 2025-05-30 | Rolfe Lindsey Director | Grant or award · Stock Option (Right to Buy) | +9,326 | 9,326 | ||
| 2025-05-30 | Patel Shami Director | Grant or award · Stock Option (Right to Buy) | +11,693 | 11,693 | ||
| 2025-05-30 | Ehrlich Christopher B Chairman and CEO | Grant or award · Stock Option (Right to Buy) | +61,843 | 61,842 | ||
| 2025-05-30 | ATWOOD BRIAN G Director | Grant or award · Stock Option (Right to Buy) | +122,549 | 122,549 | ||
| 2025-05-30 | Pierce Kristen Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +154,841 | 154,841 | ||
| 2025-05-30 | KUCHARCHUK ANDREW ALBERT Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +152,500 | 152,500 | ||
| 2025-03-31 | ATWOOD BRIAN G Director | Option exercise | +294,460 | $0.00 | $29 | 490,534 |
| 2025-03-31 | ATWOOD BRIAN G Director | Option exercise · Pre-Funded Warrant | +294,460 | $0.00 | $29 | 11,660 |
| 2025-03-04 | LAPORTE KATHLEEN Director | Grant or award · Stock Option (Right to Buy) | +17,923 | 17,923 |
Page 1 of 6 · 120 trades